You just read:

Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Sep 10, 2019, 07:30 ET